Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.

Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, Kris MG, Inoue A, Ladanyi M, Miller VA, Michor F, Pao W
Sci Transl Med. 2011 3 (90): 90ra59

PMID: 21734175 · PMCID: PMC3500629 · DOI:10.1126/scitranslmed.3002356

MeSH Terms (19)

Animals Antineoplastic Agents Carcinoma, Non-Small-Cell Lung Cell Line, Tumor Drug Resistance, Neoplasm ErbB Receptors Erlotinib Hydrochloride Evolution, Molecular Female Gefitinib Genes, erbB-1 Humans Mice Mice, Nude Models, Theoretical Mutation Neoplasm Transplantation Protein Kinase Inhibitors Quinazolines

Connections (1)

This publication is referenced by other Labnodes entities: